To Evaluate Safety and Effectiveness of RovatitanTab.

A Multicenter, Single-arm, Prospective, Observational Study to Evaluate the Safety and Effectiveness of a Fixed-dose Combination Containing Valsartan and Rosuvastatin (Rovatitan® Tablet) in Patient With Hypertension and Hypercholesterolemia

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04398771

Enrollment

1000

Registered

2020-05-21

Start date

2020-09-01

Completion date

2022-05-31

Last updated

2020-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemias, Hypertension

Brief summary

To evaluate the safety and effectiveness of a fixed-dose combination containing valsartan and rosuvastatin (Rovatitan® Tablet) in patient with hypertension and hypercholesterolemia

Detailed description

* Effectiveness: the ratio of patients who reach target BP or LDL-cholesterol * Safety: we will collect safety data

Interventions

DRUGRosuvastatin/Valsartan

Rovatitan QD for 12 weeks

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients who have hypertension and hyperlipidemia and older than 19 years * Patients who undertstand purpose and method of study, agree with study

Exclusion criteria

* Patients who have been administered Rosuvastatin/Valsartan as a anti- hyperlipiddemic/anti-hypertensive drugs * Uncontrolled hypertension (SBP\>=180mmHg or DBP\>=110mmHg) * Patients who participated another clinical study or observational study 3 months ago.

Design outcomes

Primary

Measure	Time frame	Description
The ratio of patients who reach the target BP	12weeks	SBP/DBP\<140/90mmHg (\<60years), SBP/DBP\<150/90mmHg (\>=60years)
The ratio of patients who reach the target LDLcholesterol	12weeks	target LDL refered to Hyperlipidemia pharmacotherapy

Secondary

Measure	Time frame	Description
The ratio of patients who reach the target BP and LDL-c	12weeks	SBP/DBP\<140/90mmHg (\<60years), SBP/DBP\<150/90mmHg (\>=60years), target LDL

Contacts

Primary Contactsongyi Park

songyi-park@lgchem.com=82-2-6987-4195

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026